Biomarkers for Immune Checkpoint Inhibitors in Melanoma

Immune checkpoint inhibitors have now become a standard therapy for malignant melanoma. However, as immunotherapies are effective in only a limited number of patients, biomarker development remains one of the most important clinical challenges. Biomarkers predicting clinical benefit facilitate appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitano, Shigehisa, Nakayama, Takayuki, Yamashita, Makiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058029/
https://www.ncbi.nlm.nih.gov/pubmed/30073150
http://dx.doi.org/10.3389/fonc.2018.00270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058029/
https://www.ncbi.nlm.nih.gov/pubmed/30073150
http://dx.doi.org/10.3389/fonc.2018.00270

Ejemplares similares